Ken Griffin Emergent Bio Solutions Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Emergent Bio Solutions Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 81,400 shares of EBS stock, worth $722,832. This represents 0.0% of its overall portfolio holdings.

Number of Shares

81,400

Previous 11,600 601.72%

Holding current value

$722,832

Previous $79,000 759.49%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$5.72 - $14.77 $1.86 Million - $4.81 Million	-325,866 Reduced 94.08%	20,488 $171,000
Q2 2024 Aug 14, 2024	BUY	$1.86 - $6.98 $489,708 - $1.84 Million	263,284 Added 316.94%	346,354 $2.36 Million
Q1 2024 May 15, 2024	BUY	$1.5 - $3.41 $12,264 - $27,880	8,176 Added 10.92%	83,070 $210,000
Q4 2023 Feb 14, 2024	SELL	$1.82 - $3.16 $2.05 Million - $3.56 Million	-1,125,649 Reduced 93.76%	74,894 $179,000
Q3 2023 Nov 14, 2023	BUY	$3.17 - $7.91 $1.84 Million - $4.58 Million	579,140 Added 93.2%	1,200,543 $4.08 Million
Q2 2023 Aug 14, 2023	BUY	$7.35 - $13.21 $1.35 Million - $2.43 Million	183,944 Added 42.05%	621,403 $4.57 Million
Q1 2023 May 15, 2023	BUY	$7.79 - $16.29 $1.9 Million - $3.98 Million	244,353 Added 126.54%	437,459 $4.53 Million
Q4 2022 Feb 14, 2023	SELL	$11.0 - $21.45 $4.22 Million - $8.22 Million	-383,378 Reduced 66.5%	193,106 $2.28 Million
Q3 2022 Nov 14, 2022	BUY	$20.09 - $35.8 $8.39 Million - $15 Million	417,773 Added 263.23%	576,484 $12.1 Million
Q2 2022 Aug 15, 2022	BUY	$27.42 - $43.63 $574,092 - $913,481	20,937 Added 15.2%	158,711 $4.93 Million
Q1 2022 May 16, 2022	BUY	$36.48 - $52.22 $3.04 Million - $4.35 Million	83,303 Added 152.93%	137,774 $5.66 Million
Q4 2021 Feb 14, 2022	SELL	$33.11 - $55.01 $5.89 Million - $9.79 Million	-178,007 Reduced 76.57%	54,471 $2.37 Million
Q3 2021 Nov 15, 2021	BUY	$50.07 - $66.05 $4.54 Million - $5.99 Million	90,716 Added 63.99%	232,478 $11.6 Million
Q2 2021 Aug 16, 2021	BUY	$56.61 - $80.46 $2.3 Million - $3.27 Million	40,671 Added 40.23%	141,762 $8.93 Million
Q1 2021 May 17, 2021	BUY	$86.23 - $125.19 $958,532 - $1.39 Million	11,116 Added 12.35%	101,091 $9.39 Million
Q4 2020 Feb 16, 2021	BUY	$79.17 - $111.47 $3.62 Million - $5.1 Million	45,734 Added 103.37%	89,975 $8.06 Million
Q3 2020 Nov 16, 2020	BUY	$81.91 - $134.94 $3.39 Million - $5.59 Million	41,395 Added 1454.5%	44,241 $4.57 Million
Q2 2020 Aug 14, 2020	SELL	$54.33 - $89.52 $7.18 Million - $11.8 Million	-132,129 Reduced 97.89%	2,846 $225,000
Q1 2020 May 15, 2020	SELL	$49.34 - $68.76 $642,160 - $894,911	-13,015 Reduced 8.79%	134,975 $7.81 Million
Q4 2019 Feb 14, 2020	BUY	$51.21 - $59.06 $5.06 Million - $5.83 Million	98,727 Added 200.41%	147,990 $7.98 Million
Q3 2019 Nov 14, 2019	SELL	$40.6 - $57.2 $1.69 Million - $2.38 Million	-41,686 Reduced 45.83%	49,263 $2.58 Million
Q2 2019 Aug 14, 2019	SELL	$39.92 - $53.86 $513,291 - $692,531	-12,858 Reduced 12.39%	90,949 $4.39 Million
Q1 2019 May 15, 2019	BUY	$48.23 - $66.16 $2.91 Million - $3.99 Million	60,292 Added 138.55%	103,807 $0
Q4 2018 Feb 14, 2019	SELL	$55.63 - $73.24 $2.52 Million - $3.32 Million	-45,367 Reduced 51.04%	43,515 $2.58 Million
Q3 2018 Nov 13, 2018	BUY	$52.05 - $66.51 $2.8 Million - $3.58 Million	53,849 Added 153.71%	88,882 $0
Q2 2018 Aug 10, 2018	BUY	$48.33 - $55.64 $916,771 - $1.06 Million	18,969 Added 118.08%	35,033 $0
Q1 2018 May 11, 2018	BUY	$44.44 - $54.39 $237,220 - $290,333	5,338 Added 49.77%	16,064 $846,000
Q4 2017 Feb 09, 2018	SELL	$37.77 - $47.75 $236,100 - $298,485	-6,251 Reduced 36.82%	10,726 $498,000
Q3 2017 Nov 09, 2017	BUY	$34.14 - $40.45 $579,594 - $686,719	16,977	16,977 $687,000

Others Institutions Holding EBS

# of Institutions

159

Shares Held

33.7M

Call Options Held

453K

Put Options Held

931K

View Full List

About Emergent BioSolutions Inc.

Ticker EBS
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,861,500
Market Cap $443M
Description
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...

More about EBS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account